MCM
ABMD

Mainstay Capital Management’s Abiomed Inc ABMD Stock Holding History

Mainstay Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-24
Closed -$11K – 398
2018
Q3 		$11K Hold
24
– – 0.01% 334
2018
Q2 		$10K Buy
+24
New +$8.7K 0.01% 327

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mainstay Capital Management's ABMD Position: Q4 2018 in Review

Mainstay Capital Management sold out of Abiomed Inc (ABMD) in Q4 2018, closing a stake of 24 shares — an estimated $11K sold.

Mainstay Capital Management first reported a position in ABMD in Q2 2018 and held it in 2 quarters. The position peaked at $11K in Q3 2018. 529 funds tracked by Wall St. Rank hold ABMD as of Q4 2018.

  • Mainstay Capital Management reported no remaining Abiomed Inc position as of Q4 2018 after selling out during the quarter.
  • Mainstay Capital Management sold 24 Abiomed Inc shares in Q4 2018, an estimated $11K.
  • Mainstay Capital Management first reported a position in Abiomed Inc in Q2 2018 and held it in 2 quarters.
  • Mainstay Capital Management's Abiomed Inc position peaked at $11K in Q3 2018.
  • 529 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2018.

Based on Mainstay Capital Management's 13F filing for Q4 2018, filed 8 Feb 2019.